Medpace (MEDP) fundamentals: P/E, valuation, undervalued?
Medpace · Health Care · ref. ETF XLV · price $611.57
In short — Medpace trades at 35.9× earnings (P/E), 31.7× forward, with a net margin of 17.7 % and revenue growth of +17 %. Read: Cheap for the growth (P/E 32 for ~37% growth (PEG 0.9)).
Is Medpace stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$611.57+29.3% over range
Aug 28, 25low $393.42 · high $620.75Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
25% recommend buying · 8 analysts
Valuation : Cheap for the growth — P/E 32 for ~37% growth (PEG 0.9)
Valuation
35.9
P/E (price/earnings)
31.7
Forward P/E
0.97
PEG
39.3
Price/book (P/B)
$17.1B
Market cap
17.05
EPS
Profitability & growth
17.7 %
Net margin
+17 %
Revenue growth
+37 %
Earnings growth
$144M
Total debt
Medpace income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $1.5B | $245M | 16.8 % |
| 2023 | $1.9B | $283M | 15.0 % |
| 2024 | $2.1B | $404M | 19.2 % |
| 2025 | $2.5B | $451M | 17.8 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Medpace's P/E and is the stock undervalued? What's a good P/E?
Medpace's P/E is 35.9 (forward 31.7). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Medpace profitable?
Medpace has a net margin of 17.7 % (EPS 17.05). The company is profitable.
Is MEDP stock expensive?
Our read: "Cheap for the growth" — P/E 32 for ~37% growth (PEG 0.9). Cross-check with growth and sector.
💬 A question about Medpace? The JPI assistant answers using our backtest data.
Keep exploring Medpace